- Home
- GGB vs RARE Comparison
GGB vs RARE Comparison
Compare GGB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- RARE
- Stock Information
- Founded
- GGB 1901
- RARE 2010
- Country
- GGB Brazil
- RARE United States
- Employees
- GGB N/A
- RARE N/A
- Industry
- GGB Steel/Iron Ore
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- GGB Industrials
- RARE Health Care
- Exchange
- GGB Nasdaq
- RARE Nasdaq
- Market Cap
- GGB 5.6B
- RARE 5.2B
- IPO Year
- GGB 1999
- RARE 2014
- Fundamental
- Price
- GGB $2.83
- RARE $40.00
- Analyst Decision
- GGB Strong Buy
- RARE Strong Buy
- Analyst Count
- GGB 2
- RARE 15
- Target Price
- GGB $5.00
- RARE $92.00
- AVG Volume (30 Days)
- GGB 8.5M
- RARE 1.1M
- Earning Date
- GGB 02-19-2025
- RARE 02-13-2025
- Dividend Yield
- GGB 5.14%
- RARE N/A
- EPS Growth
- GGB N/A
- RARE N/A
- EPS
- GGB 0.42
- RARE N/A
- Revenue
- GGB $11,922,358,804.00
- RARE $522,745,000.00
- Revenue This Year
- GGB N/A
- RARE $26.70
- Revenue Next Year
- GGB $4.58
- RARE $19.02
- P/E Ratio
- GGB $6.47
- RARE N/A
- Revenue Growth
- GGB N/A
- RARE 27.44
- 52 Week Low
- GGB $2.67
- RARE $37.02
- 52 Week High
- GGB $4.04
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- GGB 39.02
- RARE 35.88
- Support Level
- GGB $2.78
- RARE $39.79
- Resistance Level
- GGB $2.90
- RARE $44.52
- Average True Range (ATR)
- GGB 0.07
- RARE 2.20
- MACD
- GGB 0.01
- RARE -0.08
- Stochastic Oscillator
- GGB 50.00
- RARE 3.26
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutor, mechanical construction bars, reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives majority of the revenue from the North America Operations segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.